Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.
1 report, 1 independent
Updated Mon 00:00
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Leerink partners
U.S. investment bank
-
KROS
Slovak company
Related events
- Leerink Partners and Barclays raised price targets on Elevance Health, while MarketBeat reported consensus ratings.
- Leerink Partners cut its shares rating for Akebia Therapeutics on November 3, 2026.
- Leerink Partners decreased its target price on CVS Health, while BNP Paribas and Wyoming increased their holdings.
- Leerink Partners began coverage on Novogen Limited shares on October 20, 2026.